The FDA revised the emergency use authorization for AstraZeneca’s Evusheld antibody cocktail Feb. 24, doubling the initial dose for immunocompromised people receiving the drug.
Read the full post on Becker's Hospital Review - Healthcare News
FDA authorizes dose change for COVID-19 antibody
